Merck (MRK) has a done a lot right in cancer immunotherapy, probably more than any of its pharma rivals. But the clinical debut of a new immune-boosting drug from its early-stage cancer pipeline Saturday suggests Merck is not heeding a hard lesson learned from its biggest blunder.
The new Merck drug, called MK-1454, shows no evidence that it can kill cancer cells when injected into patients on its own, as a monotherapy. But when MK-1454 was used in combination with Merck’s checkpoint inhibitor Keytruda, the tumors in a small number of patients got smaller.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
